tirzepatide 10mg vial Buy Canada | GLP-1/GIP Research Peptide Tirzepatide (10mg Vial) Dosage Protocol

Description

Technical Specifications Retatrutide (LY3437943) Also Known As: LY3437943, GLP-3, Retatrutide acetate, Triple-G agonist, GGG triagonist, triple hormone receptor agonist CAS Number: 2381089-83-2 Molecular Weight: ~4,811 Da Half-Life: ~6 days (fatty-acid moiety enables once-weekly subcutaneous dosing in clinical study models) Receptors Targeted: GLP-1R GIPR GCGR (glucagon receptor) Form: Lyophilized (freeze-dried) powder, white to off-white Solubility: ~5mg/mL in water

Consuming tirzepatide is rarely associated with a risk of pancreatitis

Rather than being broken down by the gastrointestinal tract, fiber passes from the small intestine into the colon undigested

This dual GIP/GLP-1 receptor agonist can typically be stopped without formal tapering, but the decision should never be made independently

Genetic Factors That Influence Your Individual Response Timeline Your genetic makeupspecifically variants in genes like GLP1R, GIPR, FTO, and MC4Raffects how quickly your body responds to GLP-1 therapy